The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Association between clinical disease activity and Epstein–Barr virus reactivation in MS
Abstract
OBJECTIVE: To assess the potential significance of Epstein-Barr virus (EBV) reactivation in disease activity in MS patients. METHODS: The prevalence of antibodies against herpes simplex virus type 1 (HSV-1), HSV-2, EBV, and cytomegalovirus was determined in a group of 108 MS patients and in 163 healthy control subjects. Sera were analyzed using combinations of novel assay systems employing highly purified viral and recombinant antigens. In addition, PCR for the detection of EBV DNA was performed in serial samples. RESULTS: In contrast to the control populations, antibodies against EBV were present in 100% of MS patients. Among the tested human herpesviruses, this high extent of seropositivity was only found for EBV. Primary infection was found exclusively in the control group (3.7%), whereas serologic evidence of EBV reactivation was seen in MS patients (13. 9%) as well as control subjects (17.2%). There was no temporal coincidence between EBV reactivation and disease activity in MS patients. However, in 19 patients followed monthly for 1 year, active viral replication as measured by increased immunoglobulin (Ig) M and IgA responses to EBV early antigens (p54 + p138) and positive serum DNA was seen in 72.7% of patients with exacerbations during the study period and in none of the patients with clinically stable disease. CONCLUSIONS: The results demonstrate an association between EBV reactivation and disease activity in MS patients over time, and suggest that EBV might play an indirect role in MS as an activator of the underlying disease process.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase
Saiki, R. K., Gelfand, D. H., Stoffel, S., Scharf, S. J., Higuchi, R., Horn, G. T., Mullis, K. B., & Erlich, H. A. (1988) · Science · doi:10.1126/science.2448875 · Cited by 17,719
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Rapid and simple method for purification of nucleic acids
Boom, R., Sol, C. J., Salimans, M. M., Jansen, C. L., Wertheim-van Dillen, P. M., & van der Noordaa, J. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.3.495-503.1990 · Cited by 5,266
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Wucherpfennig, K. W., & Strominger, J. L. (1995) · Cell · doi:10.1016/0092-8674(95)90348-8 · Cited by 1,534
Fujinami, R. S., & Oldstone, M. B. A. (1985) · Science · doi:10.1126/science.2414848 · Cited by 944
CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS
SIBLEY, W. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92801-6 · Cited by 594
Perron, H., Garson, J. A., Bedin, F., Beseme, F., Paranhos-Baccala, G., Komurian-Pradel, F., Mallet, F., Tuke, P. W., Voisset, C., Blond, J. L., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.14.7583 · Cited by 484
Windhagen, A., Newcombe, J., Dangond, F., Strand, C., Woodroofe, M. N., Cuzner, M. L., & Hafler, D. A. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1985 · Cited by 463
Soldan, S. S., Berti, R., Salem, N., Secchiero, P., Flamand, L., Calabresi, P. A., Brennan, M. B., Maloni, H. W., Mcfarland, H. F., Lin, H.-C., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1394 · Cited by 445
Multiple sclerosis: In situ evidence for antibody‐ and complement‐mediated demyelination
Storch, M. K., Piddlesden, S., Haltia, M., Iivanainen, M., Morgan, P., & Lassmann, H. (1998) · Annals of Neurology · doi:10.1002/ana.410430409 · Cited by 422
Hiscock, C., & ISDALE, I. C. (1964) · PubMed · Cited by 370
Rieckmann, P., Albrecht, M., Kitze, B., Weber, T., Tumani, H., Broocks, A., Lüer, W., Helwig, A., & Poser, S. (1995) · Annals of Neurology · doi:10.1002/ana.410370115 · Cited by 334
Hemmer, B., Fleckenstein, B. T., Vergelli, M., Jung, G., McFarland, H., Martin, R., & Wiesmüller, K.-H. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.9.1651 · Cited by 313
Henle, W., Henle, G., Andersson, J., Ernberg, I., Klein, G., Horwitz, C. A., Marklund, G., Rymo, L., Wellinder, C., & Straus, S. E. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.2.570 · Cited by 207
Edwards, S., Zvartau, M., Clarke, H., Irving, W., & Blumhardt, L. D. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.6.736 · Cited by 183
Epstein-Barr Virus Antibodies in Multiple Sclerosis
Sumaya, C. V., Myers, L. W., & Ellison, G. W. (1980) · Archives of Neurology · doi:10.1001/archneur.1980.00500510052009 · Cited by 147
Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis
Bray, P. F., Bloomer, L. C., Salmon, V. C., Bagley, M. H., & Larsen, P. D. (1983) · Archives of Neurology · doi:10.1001/archneur.1983.04050070036006 · Cited by 141
Epstein‐Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis
Larsen, P. D., Bloomer, L. C., & Bray, P. F. (1985) · Neurology · doi:10.1212/wnl.35.3.435 · Cited by 138
van Sechel, A. C., Bajramovic, J. J., van Stipdonk, M. J. B., Persoon-Deen, C., Geutskens, S. B., & van Noort, J. M. (1999) · PubMed · Cited by 123
Bray, P. F., Luka, J., Bray, P. F., Culp, K. W., & Schlight, J. P. (1992) · Neurology · doi:10.1212/wnl.42.9.1798 · Cited by 122
Increased prevalence and titer of Epstein‐Barr virus antibodies in patients with multiple sclerosis
Sumaya, C. V., Myers, L. W., Ellison, G. W., & Ench, Y. (1985) · Annals of Neurology · doi:10.1002/ana.410170412 · Cited by 122
van Sechel, A. C., Bajramovic, J. J., van Stipdonk, M. J. B., Persoon-Deen, C., Geutskens, S. B., & van Noort, J. M. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.1.129 · Cited by 115
Martin, C., Enbom, M., Söderström, M. B., Fredrikson, S., Dahl, H., Lycke, J., Bergström, T. B., & Linde, A. (1997) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1997.tb00210.x · Cited by 112
A case‐control study of multiple sclerosis
Operskalski, E. A., Visscher, B. R., Malmgren, R. M., & Detels, R. (1989) · Neurology · doi:10.1212/wnl.39.6.825 · Cited by 107
Characterization of the 92,000-dalton glycoprotein induced by herpes simplex virus type 2
Marsden, H. S., Buckmaster, A., Palfreyman, J. W., et al. (1984) · Journal of Virology · doi:10.1128/jvi.50.2.547-554.1984 · Cited by 98
The significance of Epstein-Barr virus seropositivity in multiple sclerosis patients?
Munch, M., Riisom, K., Christensen, T., Møller-Larsen, A., & HAAHR, S. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00632.x · Cited by 58
HAAHR, S., Sommerlund, M., Christensen, T., Jensen, A. W., Hansen, H. J., & Møller-Larsen, A. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb38903.x · Cited by 43
Soluble HLA class I and class II antigens in patients with multiple sclerosis
Ott, M., Stecker, K., Seidl, C., Seifried, E., Westhoff, U., Grosse‐Wilde, H., & Fischer, P.-A. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03106.x · Cited by 36
Cited by
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Environmental risk factors for multiple sclerosis. Part I: The role of infection
Ascherio, A., & Munger, K. L. (2007) · Annals of Neurology · doi:10.1002/ana.21117 · Cited by 1,042
Molecular Mimicry as a Mechanism of Autoimmune Disease
Cusick, M. F., Libbey, J. E., & Fujinami, R. S. (2012) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-011-8294-7 · Cited by 606
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis: A Prospective Study
Ascherio, A., Munger, K. L., Lennette, E. T., Spiegelman, D., Hernán, M. A., Olek, M. J., Hankinson, S. E., & Hunter, D. J. (2001) · JAMA · doi:10.1001/jama.286.24.3083 · Cited by 549
Epstein–Barr virus and multiple sclerosis
Soldan, S. S., & Lieberman, P. M. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00770-5 · Cited by 467
Metadata
- Authors
- Wandinger, K.-P., Jabs, W., Siekhaus, A., Bubel, S., Trillenberg, P., Wagner, H.-J., Wessel, K., Kirchner, H., & Hennig, H.
- Venue
- Neurology
- Published
- 2000-07-25
- Volume
- 55
- Issue
- 2
- Pages
- 178-184
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1993741037
- Cited by
- 302
- References
- 30
- FWCI
- 9.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.